Association of combined PD-L1 expression and tumor-infiltrating lymphocytes features with survival and treatment outcomes in patients with metastatic melanoma

Melanoma and Skin Cancer

Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma

JAMA Dermatol.

Brunot A, Grob JJ, Jeudy G, Grange F, Guillot B, Kramkimel N, Mortier L, Le Corre Y, Aubin FF, Mansard S, Lebbé C, Blom A, Montaudie H, Giacchero D, Prey S, Legoupil D, Guyot A, Amini-Adle M, Granel-Brocard F, Meyer N, Dinulescu M, Edeline J, Campillo-Gimenez B, Lesimple T

doi: 10.1001/jamadermatol.

Melanoma and Skin Cancer

Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma

Melanoma Res

Adams AM, Chick RC, Vreeland TJ, Clifton GT, Hale DF, McCarthy PM, O'Shea AE, Bohan PMK, Hickerson AT, Park H, Sloan AJ, Hyngstrom J, Berger AC, Jakub JW, Sussman JJ, Shaheen M, Wagner T, Faries MB, Peoples GE

doi: 10.1097/CMR.0000000000000758

Melanoma and Skin Cancer

Association of Mohs Micrographic Surgery vs Wide Local Excision With Overall Survival Outcomes for Patients With Melanoma of the Trunk and Extremities

★ 2 Recommended by Alexander Meisel, Faculty Member

JAMA Dermatol

Demer AM, Hanson JL, Maher IA, Liszewski W

doi: 10.1001/jamadermatol.2020.3950

Melanoma and Skin CancerImmunotherapy

Prognostic Role of Tumoral PDL1 Expression and Peritumoral FoxP3+ Lymphocytes in Vulvar Melanomas

Hum Pathol.

Chłopik A, Selim MA, Peng Y, Wu CL, Tell-Marti G, Paral KM, Shalin SC, Kraft S, Hsu CK, Shea CR, Puig S, Fernandez-Figueras MT, Biernat W, Ryś J, Marszalek A, Hoang MP

Melanoma and Skin Cancer

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

N Engl J Med.

Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, Smylie M, Dummer R, Hill A, Hogg D, Haanen J, Carlino MS, Bechter O, Maio M, Marquez-Rodas I, Guidoboni M, McArthur G, Lebbé C, Ascierto PA, Long GV, Cebon J, Sosman J, Postow MA, Callahan MK, Walker D, Rollin L, Bhore R, Hodi FS, Larkin J

doi: 10.1056/NEJMoa1709684.

Melanoma and Skin Cancer

Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib

Eur J Cancer

Saiag P, Robert C, Grob JJ, Mortier L, Dereure O, Lebbe C, Mansard S, Grange F, Neidhardt EM, Lesimple T, Machet L, Bedane C, Maillard H, Dalac-Rat S, Nardin C, Szenik A, Denden A, Dutriaux C

doi: 10.1016/j.ejca.2021.05.031

Melanoma and Skin Cancer

Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials

J Clin Oncol.

Schadendorf D, Wolchok JD, Hodi FS, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Chesney J, Robert C, Grossmann K, McDermott D, Walker D, Bhore R, Larkin J, Postow MA

doi: 10.1200/JCO.2017.73.2289.

Melanoma and Skin CancerT Cells

Decline of PD-1 positive circulating T regulatory cells predicting more favorable clinical outcome of melanoma patients under immune checkpoint blockade

Br J Dermatol.

Gambichler T, Schröter U, Höxtermann S, Susok L, Stockfleth E, Becker JC

doi: 10.1111/bjd.18379.

Melanoma and Skin Cancer

PD-1 and PD-L1 inhibitors in the treatment of non-melanoma skin cancer: a systematic review

J Am Acad Dermatol.

Choi FD, Kraus CN, Elsensohn AN, Carley SK, Lehmer LM, Nguyen RT, Linden KG, Shiu J

doi: 10.1016/j.jaad.2019.05.077.

Related content

Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma

Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma

Association of Mohs Micrographic Surgery vs Wide Local Excision With Overall Survival Outcomes for Patients With Melanoma of the Trunk and Extremities

Prognostic Role of Tumoral PDL1 Expression and Peritumoral FoxP3+ Lymphocytes in Vulvar Melanomas

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib

Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials

Decline of PD-1 positive circulating T regulatory cells predicting more favorable clinical outcome of melanoma patients under immune checkpoint blockade

PD-1 and PD-L1 inhibitors in the treatment of non-melanoma skin cancer: a systematic review